| INTRODUCTION
Retinoblastoma is the most common malignant tumour of the eye in childhood, affecting approximately 1:20 000 live births. 1 It occurs in differentiating cone precursor cells of the developing retina that have predisposing mutations in both copies of the tumour suppressor gene RB1. [2] [3] [4] Retinoblastoma is bilateral in about 40% of cases with a median age of diagnosis of 12 months. 5 The other 60% of affected individuals have unilateral retinoblastoma with a median age of diagnosis of 24 months. Nearly all cases of bilateral retinoblastoma, and 17% to 18% of cases of unilateral retinoblastoma, 6, 7 are due to an inherited or de novo heterozygous germline mutation in RB1 and are therefore subsequently hereditary segregating in an autosomal dominant pattern. The remainder of the bilateral cases and some unilateral cases are caused by mosaicism for a mutation, which may be present in the germline. Around 83% of unilateral retinoblastoma is non-hereditary, occurring due to somatic mutations in both copies of RB1 in the same retinal cell. The heritability of retinoblastoma determines the risks of retinoblastoma for siblings and children of the affected individual, which vary from <1% to 50% based on empiric data. 7, 8 Current molecular genetic screening techniques detect up to 95% of germline RB1 mutations in leucocytes of individuals with hereditary retinoblastoma. 7, 9 Identifying whether or not an individual has hereditary retinoblastoma is essential for appropriate clinical management, determining the need for frequent follow-up examination under anaesthesia (EUA) for early detection of newly arising tumours.
Molecular genetic testing is also essential for optimal management of other family members. Detection of a germline RB1 mutation antenatally or postnatally identifies babies at a high risk of developing retinoblastoma who will benefit from intensive ophthalmic surveillance from birth (Table S1 , Supporting information, for Birmingham
Children's Hospital High Risk Screening Protocol). Frequent examinations including EUAs enable timely detection of tumours, reducing the likelihood that enucleation, radiotherapy, and/or chemotherapy will be required, and helping preserve vision and reduce morbidity.
Babies who are found not to have inherited the familial RB1 mutation do not require ophthalmic surveillance, avoiding unnecessary and burdensome EUA and the attendant risks of anaesthesia. In a small number of cases with unilateral retinoblastoma where it cannot be proven that the disease is not germline a modified screening protocol is followed for the siblings and offspring of the affected family member (Table S1 
| Audit interpretation
Each questionnaire was given an "Audit Interpretation"
(AI) assessment of the individual's understanding of the genetic implications of their retinoblastoma based on the answers they gave to the questions regarding the risk of retinoblastoma for siblings and children. The data recorded was the individuals "own understanding"
of the retinoblastoma risk and may be different to that which was imparted to them, which in many circumstances may be via a third party such as their parents, or several different doctors over a period of time. The AI was deemed to be "Correct," "Incorrect," "No information" if risks were not given, "Out of date" if the risk given was based on out of date information, or "Unable to assess" if the true risk was impossible to ascertain based on the clinical information available from the questionnaire. All questionnaires were assessed by an experienced genetic counsellor (LB, LB, or SC) and verified by a second author single author (TC). There were a very small number of cases where a difference of opinion arose. These cases were discussed within the genetic counselling and consultant team and a consensus arrived at in all cases.
| Exclusion criteria
Individuals under 16 years of age and older than 45 were excluded for the purposes of this audit analysis, which was to assess individuals' reproductive knowledge at the current time. Individuals younger than 16 would most likely have future genetic counselling planned at transition or in adulthood and those older than 45 were considered unlikely to be planning further children.
Individuals who did not specify whether their retinoblastoma was unilateral or bilateral were also excluded from data analysis.
| Laterality
Cases were grouped into bilateral, hereditary unilateral and non-hereditary unilateral. The unilateral cases are divided into hereditary and nonhereditary based on reported family history and therefore the true percentage of hereditary cases in the unilateral group will be higher due to undetected de novo germline mutations. Throughout the paper, the term "non-hereditary unilateral" refers to the presumed non-hereditary cases.
The small number of hereditary unilateral cases are considered as a separate group as although the risk of children inheriting the RB1 mutation is 50% as in the bilateral cases, the penetrance is much lower. Furthermore, their perception of the significance of unilateral disease is likely to be different from those individuals with bilateral disease, having significantly less impact for visual impairment and a lower risk for second non-retinoblastoma primary tumours.
| Statistics
GraphPad software was used to perform χ 2 testing and Fisher's exact test in statistical analysis of the data.
3 | RESULTS
| Demographics and laterality
A total of 575 letters were sent to GPs and 569 replies were received. In 6 cases it was deemed not appropriate to contact the patient and a total of 563 patient letters were sent out. There were 471 respondents (return rate 84%). 108 were under 16 years of age and 29 were older than 45 and were therefore excluded. Another 42 individuals did not specify whether their retinoblastoma was unilateral or bilateral and were also excluded from data analysis.
A total of 292 individuals aged 16 to 45 were therefore included 
| Follow-up
In the bilateral group, 48% (48 of 100) and in the non-hereditary uni- 
| Reproduction

| DISCUSSION
| Rates of genetic testing
Overall, the audit found that reported rates of genetic testing were surprisingly low in both unilateral and bilateral groups. Part of the explanation for this is that genetic testing only became routinely available in the mid to late 1990s for bilateral retinoblastoma and even later for unilateral retinoblastoma. The participants in the audit were all born before 1995 and therefore would not have been offered testing at the time of diagnosis, and would have had to be offered or seek testing at a later date. It is now routine practice to offer genetic testing in all cases of retinoblastoma.
An additional potential reason for low reported rates of genetic testing is that because of the natural history of retinoblastoma, patients will be diagnosed and undergo testing in childhood, and therefore as adults may be unaware of previous genetic testing. It is possible that in some cases, parents might have withheld information from a child in an effort to protect the child from worrisome news. Knowledge of having had a genetic test depends on this information being passed on by a parent, or through a follow-up appointment in adolescence or adulthood with the healthcare system.
| Understanding of genetic test results
Individuals with bilateral retinoblastoma were more likely to be able to give accurate risks for siblings and children. This may be due to the fact that genetic test results in unilateral retinoblastoma are more likely to be incomplete or uninformative and more complicated than in bilateral disease and therefore assessing risk is more complex. In 
| Follow-up
Long-term follow-up for retinoblastoma in the UK is typically organized back with the referring centre, especially for unilateral disease. It should however include oncology input in a "late effects" service for those who had bilateral disease or any case that required either chemotherapy or radiotherapy. About 48% of individuals with bilateral retinoblastoma and 14% of those with unilateral retinoblastoma reported being under longterm follow-up. Of those individuals not currently under follow-up with oncology or ophthalmology, almost half requested that this be arranged.
This was true for both unilateral and bilateral groups, indicating a clear desire by adults with retinoblastoma for ongoing medical follow-up.
| Reproduction
Overall a surprisingly low proportion of the cohort reported having children, for example 38% (14/37) of women in the 36 to 45 years age group did not have children compared to 19% of 45-year-old women in the general population in the UK. 11 We identified a clear relationship between genetic testing and understanding the genetic implications of retinoblastoma and having children in both unilateral and bilateral groups, which was especially striking in female participants. From the audit data we cannot identify the cause and effect. The association may be due to individuals wanting children actively seeking out genetic testing; alternatively, it may be that individuals who are unaware of the risks and reproductive choices are deciding not to have children. Our finding that over 80% (43 of 52) of women with nonhereditary unilateral retinoblastoma who were unaware of genetic FIGURE 2 The percentage of respondents who had children. Knowing the results of genetic testing was significantly associated with having children in female respondents but not male respondents test results had no children might suggest that it is the lack of genetic information that is influencing reproductive decisions.
Previous work exploring reproductive decision making in retinoblastoma has identified patient perception of risk as an important factor. Dommering et al found that retinoblastoma had a significant impact on reproductive behaviour in a cohort of patients who had undergone genetic testing, with perceived risk as opposed to actual risk being the most important factor. 12, 13 A study of other inherited retinal disorders identified that affected individuals had a deep anxiety about passing on visual impairment to their children, and some had chosen not to have children because the risk was "too high." 14 We must also consider that a lack of clinical information patients have regarding developments in treatment of retinoblastoma and an "unawareness" of better outcomes compared to the past might be influencing individuals' decisions not to have children.
Many children under surveillance because of an identified risk of retinoblastoma will now be treated by local therapy only (eg, laser/ cryotherapy) and avoid the morbidity associated with enucleation, chemotherapy and/or external beam radiotherapy. Individuals who have experienced the morbidity associated with older treatments may choose not to have children to avoid side effects they feel are unacceptable and not be aware of these new therapies. Follow-up in a late effects clinic would give patients the opportunity to discuss future management and outcomes.
A lack of information regarding new reproductive technologies such as PGD may also be playing an important role. We found 100%
of women with bilateral retinoblastoma who did not know their genetic test results had no children, a highly surprising figure. This may reflect a lack of awareness of the options now available that enable individuals to have children without retinoblastoma and anecdotal evidence of this was seen in the audit.
There are potentially other confounding factors, such as social factors, body image, and self-esteem issues that may be related to facial asymmetry or visual impairment, many of which will be avoided with newer treatment, but which may still be influencing reproductive rates in individuals with retinoblastoma. Further investigation, ideally through a qualitative research study, is warranted to explore the reasons for the low reproductive rates in individuals with retinoblastoma identified by this study.
The results of this large scale national audit suggest that individuals may be making life choices based on incomplete or inaccurate information. It is vital for health care professionals to ensure young adults who were diagnosed with retinoblastoma in childhood have up to date genetic test results and fully understand the implications of these results. This is necessary to inform their own medical care, to enable them to make informed reproductive decisions, and to ensure that optimal care is provided to children who are born at risk of retinoblastoma. In this era of mainstreaming genetics we must ensure that embedding clinical genetics in transition care is seen as a priority.
